FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029632009> ?p ?o ?g. }

• W3029632009 abstract "589 Background: The Katherine trial has shown that adjuvant T-DM1 improved invasive disease free survival (iDFS) of patients with HER2+ breast cancer who did not achieve a pathological complete response (pCR) with trastuzumab-based neoadjuvant chemotherapy (NAC). However, some subgroups may benefit less from this treatment escalation. Methods: All HER2+ breast cancer patients treated with trastuzumab-based NAC between 2006 and 2016 were retrieved from our institution’s database. Neo- or adjuvant T-DM1 was an exclusion criterion. We then selected the patients who did not achieve a pCR and analyzed the outcome (iDFS and overall survival (OS)) according to ypT, ypN and several factors analyzed in the Katherine trial. Results: Out of the 182 patients, 117 patients reached the inclusion criteria. Patient’s characteristics were similar to the trastuzumab arm of the Katherine trial. With a median follow-up of 75.4 months (29.3–149.7), 28 events (24%) occurred, among which 22 distant relapses. In univariate analysis, ≤ypT1 vs > ypT1, ypN0 vs ypN+, no capsular rupture, signs of histological response (Sataloff not D in T or N) were associated with a better iDFS. In multivariate analysis, only ypT status remained significant. Of note, patients with ≤ypT1 (ypTis, ypT0, ypTmic, ypT1) (n = 81; 69%) had an excellent outcome: 3 years (y) and 5y iDFS rates of 90% (83.6-96.8) and 88.6% (81.9-95.9) respectively. The remaining patients (n = 36; 31%) had a significantly lower 3y and 5y iDFS: 69.2% (55.6-86.2) and 59.5% (45-78.6) respectively (p = 0.0017). OS in a multivariate analysis was also improved in pts with the smaller residual and/or node negative disease (3y OS rates of 100% (100-100) vs 92.1% (85.7-99); 5y OS rates of 96% (90.7-100) vs 81.1% (71.6-91.9); p = 0.02). Conclusions: In the absence of pCR after trastuzumab-based NAC, patients with pathological response scored as ≤ypT1 (ypTis,ypT0, ypTmic, ypT1) have an excellent outcome. These patients may derive less benefit from adjuvant T-DM1." @default.
• W3029632009 created "2020-06-05" @default.
• W3029632009 creator A5009701332 @default.
• W3029632009 creator A5009791655 @default.
• W3029632009 creator A5033718301 @default.
• W3029632009 creator A5034544552 @default.
• W3029632009 creator A5044752757 @default.
• W3029632009 creator A5058100097 @default.
• W3029632009 creator A5071553983 @default.
• W3029632009 creator A5072122778 @default.
• W3029632009 creator A5072988299 @default.
• W3029632009 creator A5081090165 @default.
• W3029632009 creator A5089096629 @default.
• W3029632009 date "2020-05-20" @default.
• W3029632009 modified "2023-09-23" @default.
• W3029632009 title "Long-term outcomes of patients with HER2+ breast cancer with small-size residual disease (≤ypT1) in the absence of pathological response after trastuzumab-based neoadjuvant chemotherapy and without adjuvant T-DM1: A monocentric retrospective study." @default.
• W3029632009 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.589" @default.
• W3029632009 hasPublicationYear "2020" @default.
• W3029632009 type Work @default.
• W3029632009 sameAs 3029632009 @default.
• W3029632009 citedByCount "0" @default.
• W3029632009 crossrefType "journal-article" @default.
• W3029632009 hasAuthorship W3029632009A5009701332 @default.
• W3029632009 hasAuthorship W3029632009A5009791655 @default.
• W3029632009 hasAuthorship W3029632009A5033718301 @default.
• W3029632009 hasAuthorship W3029632009A5034544552 @default.
• W3029632009 hasAuthorship W3029632009A5044752757 @default.
• W3029632009 hasAuthorship W3029632009A5058100097 @default.
• W3029632009 hasAuthorship W3029632009A5071553983 @default.
• W3029632009 hasAuthorship W3029632009A5072122778 @default.
• W3029632009 hasAuthorship W3029632009A5072988299 @default.
• W3029632009 hasAuthorship W3029632009A5081090165 @default.
• W3029632009 hasAuthorship W3029632009A5089096629 @default.
• W3029632009 hasConcept C121608353 @default.
• W3029632009 hasConcept C126322002 @default.
• W3029632009 hasConcept C143998085 @default.
• W3029632009 hasConcept C207103383 @default.
• W3029632009 hasConcept C2776694085 @default.
• W3029632009 hasConcept C2777863537 @default.
• W3029632009 hasConcept C2779786085 @default.
• W3029632009 hasConcept C44249647 @default.
• W3029632009 hasConcept C530470458 @default.
• W3029632009 hasConcept C71924100 @default.
• W3029632009 hasConceptScore W3029632009C121608353 @default.
• W3029632009 hasConceptScore W3029632009C126322002 @default.
• W3029632009 hasConceptScore W3029632009C143998085 @default.
• W3029632009 hasConceptScore W3029632009C207103383 @default.
• W3029632009 hasConceptScore W3029632009C2776694085 @default.
• W3029632009 hasConceptScore W3029632009C2777863537 @default.
• W3029632009 hasConceptScore W3029632009C2779786085 @default.
• W3029632009 hasConceptScore W3029632009C44249647 @default.
• W3029632009 hasConceptScore W3029632009C530470458 @default.
• W3029632009 hasConceptScore W3029632009C71924100 @default.
• W3029632009 hasLocation W30296320091 @default.
• W3029632009 hasOpenAccess W3029632009 @default.
• W3029632009 hasPrimaryLocation W30296320091 @default.
• W3029632009 hasRelatedWork W13534514 @default.
• W3029632009 hasRelatedWork W14328058 @default.
• W3029632009 hasRelatedWork W16909223 @default.
• W3029632009 hasRelatedWork W2422317 @default.
• W3029632009 hasRelatedWork W5387012 @default.
• W3029632009 hasRelatedWork W5453825 @default.
• W3029632009 hasRelatedWork W6779540 @default.
• W3029632009 hasRelatedWork W6809237 @default.
• W3029632009 hasRelatedWork W8421587 @default.
• W3029632009 hasRelatedWork W8464406 @default.
• W3029632009 isParatext "false" @default.
• W3029632009 isRetracted "false" @default.
• W3029632009 magId "3029632009" @default.
• W3029632009 workType "article" @default.